Erbitux First-Line Studies Face Enrollment Challenges From Avastin
Executive Summary
ImClone is moving Erbitux development forward with an eye on enrollment
You may also be interested in...
Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products
Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies
Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products
Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies
Erbitux Priced For Late Stage Use, ImClone Says; McKesson Is Sole Distributor
The pricing strategy for the oncologic Erbitux reflects the expectation that the biologic will be used primarily in late stage disease, ImClone CEO Daniel Lynch told analysts during a March 15 conference call